Risk Factors & Patho
Screening & Diagnosis
Medications & Mechanisms
Medications & Mechanisms #2
Clinical Pearls
100

Osteoporosis is characterized by decreased ____ leading to increased risk of ____

Osteoporosis is characterized by decreased BMD leading to increased risk of fragility fractures

100

Osteoporosis can be diagnosed with a T score of _____

≤-2.5

100

Denosumab binds to ____ reducing osteoclast activity and bone resorption

RANK-L

100

First-line agents for treatment and prevention of osteoporosis due to evidence in preventing spine, hip, and non-vertebral fractures

Bisphosphonates

100

Adequate supplementation with calcium and Vitamin D is necessary prior to initiation of bisphosphonates to prevent________ 

hypocalcemia

200

What cells play a role in bone resorption?

Osteoclasts

200

What are common locations for fragility fractures?

Spine, hip, and wrist

200

How often is Denosumab dosed?

Sub Q every 6 months

200

Efficacy of Romosozumab diminishes after ____

12 months

200

Peripheral edema is a side effect associated with which anti-resorptive agent(s)?

Denosumab & Raloxifene

300

True or False: High BMI is a risk factor for osteoporosis

False, low BMI

300

FRAX tool is used to predict...?

10-year risk of hip fractures and major osteoporotic fractures (spine, forearm, hip, or shoulder)

300

This hormone analog stimulates osteoblast activity and is used for patients at very high fracture risk, but its use is limited to 18-24 months

Teriparatide (Forteo)

300

Protein C, S, or antithrombin deficiency is a contraindication to use of ____

Conjugated Estrogens/Bazedoxifene (Duavee)

300

which bisphosphonate may have better GI tolerability?

Risedronate

400

How does estrogen deficiency lead to increased bone resorption?

Increased RANK-L expression and osteoclast differentiation

400

A high fracture risk using the FRAX tool is defined as: 

major osteoporotic fracture probability of ≥20% or a 10-year hip fracture probability of ≥3%

400

Raloxifene is not considered a first line agent due to lack of efficacy in reducing what kind of fractures?

Hip or non-vertebral fractures

400

After completing Abaloparatide therapy, transitioning to _________ is advised to maintain bone density gains

Bisphosphonates

400

________ should be avoided in patients with high risk of endometrial cancer, CV disorders, and probable dementia

Conjugated estrogen + bazedoxifene

500

How does Vitamin D deficiency lead to low BMD?

Decreased calcium reabsorption, up-regulation of PTH and RANK-L expression

500

You have a 67 year old female patient with primary hyperparathyroidism. How often can you perform a DEXA scan for her billed through Medicare part B?

every 2 years

500

Maximum duration of therapy with calcitonin is limited to ______ due to increased risk for _______

6 months, Malignancy

500

Romosozumab inhibits __________ , regulatory factor in bone metabolism that inhibits Wnt/Beta-catenin signaling pathway regulating bone growth

Sclerostin

500

Black box warning for _____ 

"SHOULD NOT be initiated in patients with acute CVA in previous year"


Romosozumab

M
e
n
u